Synergy Rx Recalls Human Chorionic Gonadotropin Tablets Due to Sterility Concerns
Synergy Rx is recalling Human Chorionic Gonadotropin tablets because the product lacks assurance of sterility and has CGMP deviations.
The agency’s classification
FDA (Drugs): Class II
Class II is a situation in which use of or exposure to a violative product may cause temporary or medically reversible adverse health consequences, or where the probability of serious adverse health consequences is remote.
This is the agency’s own classification, taken from its notice. The severity score below is our assessment, not the agency’s. How recall classes work
What this means for you
Our assessment, not the agency’s: severity 4/5 (Severe).
The hazard poses a serious risk of illness, injury, or structural failure. Stop using the product immediately and contact the manufacturer for a refund or repair.
Our severity reasoning: The recall is classified as FDA Class II, and the rubric specifies that FDA Class II recalls with potential for significant injury or hospitalization (implied by sterility failure in a drug) are rated as Severe.
Plain-English summary
Synergy Rx is recalling Human Chorionic Gonadotropin tablets in 300 IU and 500 IU strengths. The recall is due to a lack of assurance of sterility and Current Good Manufacturing Practice (CGMP) deviations.
The affected product is prescription-only and was distributed nationwide within the United States. The recall covers all lots of the product.
Consumers should stop using the product and contact their healthcare provider or the recalling firm for further instructions.
The recalled product
- Product
- HUMAN CHORIONIC GONADOTROPIN in 300IU and 500 IU TABLETS, Rx only, Synergy RX, 4901 Morena Blvd # 504-A San Diego, CA 92117 (855) 792-6676
- Manufacturer
- Synergy Rx
- Category
- Drug — Prescription Medication
Is your product affected?
Check your packaging against the codes below. If any of them match, the product is part of this recall.
Lot numbers (1)
- All Lots
Distribution
Distributed nationwide across the United States.
Part of a larger recall action
This product is one of 81 recalled by Synergy Rx under a single FDA (Drugs) recall action. The agency files each product separately, so the size of the action is not visible from this page alone.
See all 81 products in this recall →Related recalls
Same manufacturer · Synergy Rx
See all →- SevereSynergy Rx Recalls Lidocaine Creams Due to Sterility Assurance Issues
FDA (Drugs) · 2017-03-22
- HighSynergy Rx Recalls Ultra Lite Cream Due to Sterility Concerns
FDA (Drugs) · 2017-03-22
- SevereSynergy Rx Recalls Lactic Acid Solution Due to Sterility Concerns
FDA (Drugs) · 2017-03-22
- HighSynergy Rx Modified Jessner Peel Recalled for Sterility Assurance Issues
FDA (Drugs) · 2017-03-22
- SevereSynergy Rx Recalls CLEAR 2 Due to Sterility Assurance Concerns
FDA (Drugs) · 2017-03-22
Same hazard · sterility failure
See all →- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereAvKare Carboxymethylcellulose Sodium Eye Drops Recalled for Sterility Concerns
FDA (Drugs) · 2026-09-30
- SevereROHTO DIGI-EYE Eye Drops Recalled Over Sterility Assurance Gap
FDA (Drugs) · 2026-07-29
- HighROHTO DRY-AID Eye Drops Recalled Due to Sterility Concerns
FDA (Drugs) · 2026-07-29
- SevereOne-Piece Introducer Tray kits recalled for sterility failure
FDA (Devices) · 2026-07-22
Similar recalls
- SeverePharm D Solutions Recalls Human Chorionic Gonadotropin Vials Due to Sterility Concerns
FDA (Drugs) · 2018-12-26
- SeverePharm D Solutions Recalls Human Chorionic Gonadotropin Vials for Sterility Concerns
FDA (Drugs) · 2019-06-19
- SeverePharmcore Recalls Human Chorionic Gonadotropin Vials Due to Sterility Concerns
FDA (Drugs) · 2018-09-05
- SevereKRS Global Biotechnology Recalls Human Chorionic Gonadotropin Due to Sterility Concerns
FDA (Drugs) · 2019-10-09
- SevereFDA Recalls Chorionic Gonadotropin Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04
- SevereFDA Recalls Compounded Chorionic Gonadotropin Syringes Due to Sterility Concerns
FDA (Drugs) · 2015-11-04